BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 24104591)

  • 1. [Chronic lymphocytic leukemia].
    Maurer C; Hallek M
    Dtsch Med Wochenschr; 2013 Oct; 138(42):2153-66. PubMed ID: 24104591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Watch and Wait in Lebanese Chronic Lymphocytic Leukemia Patients: How Relevant is it?
    Lutfallah AA; Kourie HR; Eid R; Farhat F; Ghosn M; Kattan J
    Asian Pac J Cancer Prev; 2016; 17(1):215-7. PubMed ID: 26838212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic lymphocytic leukemia--the old and the new].
    Korte W; Cogliatti S
    Ther Umsch; 2004 Feb; 61(2):151-6. PubMed ID: 15018398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
    Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
    Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic lymphatic leukemia].
    Lechner K; Bilbeisi S; Wittmann E; Wilfing A
    Wien Klin Wochenschr; 1994; 106(10):291-9. PubMed ID: 8053196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia.
    Keating MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
    J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
    Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
    Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
    Shvidel L; Berrebi A
    Expert Rev Hematol; 2016 Mar; 9(3):245-54. PubMed ID: 26613391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
    Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of chronic lymphocytic leukaemia.
    Kalil N; Cheson BD
    Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.